Trial Profile
A comparative study of related outcomes of Fludarabine plus busulfan (FB) and fludarabine plus melphalan (FM) in reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (SCT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jan 2016
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary) ; Melphalan
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- 21 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology